Background <p>Peritoneal metastasis (PM) from gastric cancer (GC) is associated with poor prognosis and limited treatment options. We investigated a novel peritoneal-targeted therapy using CF33-human sodium iodide symporter (hNIS), a chimeric orthopoxvirus, combined with anti-PD-L1 immune checkpoint blockade in an immunocompetent mouse model of GCPM.</p> Methods <p>We evaluated replication and cytotoxicity of CF33-hNIS in human and murine GC cell lines.…
Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory
Journal for ImmunoTherapy of Cancer | | Yang, A., Zhang, Z., Park, A. K., Chaurasiya, S., Kim, S.-I., Lu, J., Vashi, Y., Cillis, J., Valencia, H., Chen, C., Deshpande, S., Fong, Y., Woo, Y.
Topics: stomach-cancer, immunotherapy, targeted-therapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer